ABSTRACT
A newborn presented with erythematous lesion over face, which appeared soon after birth. Diagnosis of neonatal lupus erythematosus (NLE) was confirmed by positive anti-Ro SSA antibody and skin biopsy. But anti-La SSB antibody was negative. Her hepatic transaminases were high. But no cardiac manifestations were noted.
Subject(s)
Antibodies, Antinuclear/immunology , Diagnosis, Differential , Face , Female , Humans , Infant, Newborn , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Cutaneous/immunology , Prognosis , Ribonucleoproteins/immunologySubject(s)
Humans , Bibliographies as Topic , Cancer Vaccines , Langerhans Cells/physiology , Dendritic Cells/physiology , Antigen Presentation/physiology , Langerhans Cells/classification , Langerhans Cells/immunology , Dendritic Cells/classification , Dendritic Cells/immunology , Immune System , Lupus Erythematosus, Cutaneous/immunology , Lupus Erythematosus, Systemic/immunology , Immunologic Memory/physiology , NeoplasmsABSTRACT
Twenty patients with exclusion criteria for common risk factors for acute myocardial infarction [AMI] were selected for this study in addition to 20 healthy volunteer subjects matched for age and sex and had no risk factors for AMI or a past history of anginal pain or strokes or a family history of previous thromboembolic events. The study concluded that six patients in the study group showed high to moderate positive IgG-ACLA test in comparison with three subjects in the control group. The presence of ACLA in the early stage of AMI and its persistence one week after suggested its contribution in the pathogenesis of AMI rather than being a result of its occurrence
Subject(s)
Humans , Male , Female , Antibodies, Anticardiolipin , Electrocardiography , Myocardial Ischemia , Lupus Erythematosus, Cutaneous/immunologySubject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Adolescent , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Discoid/diagnosis , Acute Disease , Chronic Disease , Lupus Erythematosus, Cutaneous/immunology , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Discoid/immunology , Surveys and QuestionnairesABSTRACT
O lúpus eritematoso cutâneo subagudo (LECS) é observado em cerca de 10 por cento dos pacientes com LE e foi caracterizado em 1979, por Sontheimer. A fotossensibilidade é marcante e o curso clínico relativamente benigno com febre, astenia e envolvimento do sistema nervoso central. O comprometimento renal é raro e quando ocorre é de forma discreta. O tratmento na maioria dos pacientes consiste de protetores solares, corticosteróides tópicos e antimaláricos.
Subacute cutaneous lupus erythematosus (SCLE) is in about 10% of patients with LE and it was characterized, in 1979, by Sontheimer. This subset exhibits prominent photosensitivity and relatively benign course. Fever, malaise and central nervous system involvement occur. Renal disease is mild and infrequent. SCLE condition in most patients is controlled with sunscreens, topical corticosteroid and antimalarial drugs.
Subject(s)
Humans , Male , Female , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Cutaneous/physiopathology , Lupus Erythematosus, Cutaneous/immunology , Lupus Erythematosus, Cutaneous/therapy , Autoimmunity , Fluorescent Antibody TechniqueABSTRACT
One hundred and twenty-six patients with LE were studied. They were distributed as follows: 84 with DLE, 13 with SALE and 29 with SLE. Biopsies from the skin lesions were performed and submitted to DIF. Positive results were equal to 69,61.5 and 72.4 percent of the DLE,SALE and SLE cases, respectively. These data are in accordance with the literature. IgM was the most frequently found immunoglobulin, followed by the association IgM+C3.
Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Immunoglobulins/analysis , Lupus Erythematosus, Discoid/immunology , Lupus Erythematosus, Cutaneous/immunology , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Discoid/diagnosis , Reproducibility of Results , Sensitivity and Specificity , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Systemic/diagnosis , Fluorescent Antibody Technique, DirectABSTRACT
Los pacientes con lupus eritematoso presentan múltiples manifestaciones de enfermedad autoinmune, algunas de las cuales han sido asociadas con alteraciones de la inmunidad celular. Existen estudios que señalan a la piel como sitio primario de lupus eritematoso, y al sistema inmune cutáneo con un papel preponderante. En el presente estudio se caracterizaron diferentes subpoblaciones leucocitarias utilizando anticuerpos específicos y la técnica de la avidina-biotina inmunoperoxidasa. Las lesiones de Lupus Eritematoso Sistémico (LES) presentaron un incremento significativo (p<0,05) de linfocitos T cooperadores-inductores CD4+ linfocitos T supresores-citotóxicos CD8+, linfocitos T alfa ß y la molécula de adhesión LFA-1ß, en relación con piel no lesionada y piel sana control. Por su parte, los linfocitos T y las células CD25+ (receptor Interleucina-2) estaban disminuidas en las lesiones de LES en relación con piel no lesionada y piel sana control. Las lesiones de Lupus Eritematoso Discoideo Crónico (LEDC) también presentaron un aumento significativo (p<0,05) de linfocitos T CD4+, CD8+, ß+ y LFA-1ß +, y una disminución en el número de células + y CD25+. La epidermis en las lesiones de LES y LEDC mostró una disminución de células de Langerhans CD1a+ ausencia de HLA-DR por parte de los queratinocitos, y expresión de la molécula de interacción celular ICAM-1 limitada a pequeños grupos de queratinocitos. Las diferencias y alteraciones observadas pudieran contribuir con el proceso patológico en lupus eritematoso, y señalan un posible defecto a nivel del compromiso epidérmico
Subject(s)
Adolescent , Adult , Middle Aged , Humans , Lupus Erythematosus, Cutaneous/immunology , Skin ManifestationsABSTRACT
O lupus eritematoso sistemico (LES) e uma doenca auto-imune que afeta mulheres durante a idade reprodutora. Os autores discutem os efeitos da gestacao no lupus, sendo que as condicoes ideais para a paciente lupica engravidar seriam: dois anos do diagnostico da doenca, no minimo apos 6 meses de remissao da doenca e nivel de creatinina serica previa a gestacao < 1,6mg/dl. Fatores de mau prognostico durante a gestacao seriam: atividade da doenca na concepcao e diagnostico de lupus durante a gestacao. As complicacoes do LES na gestacao a caracterizam como gestacao de altissimo risco: perdas fetais de 29 por cento, prematuridade de 15 a 20 por cento e crescimento intra-uterino retardado de 30 por cento dos casos. A presenca da sindrome antifosfolipide e de grande risco para a gestacao, elevando as perdas fetais ate 90 por cento. O tratamento mais efetivo para esta complicacao ainda nao esta estabelecido. A sindrome de lupus neonatal esta associada com a presenca do anticorpo anti-RO/anti-La e caracteriza-se por um quadro cutaneo transitorio sem sequelas e pela presenca de BAV congenito que e definitivo, porem infrequente (1,5 por cento). Os autores sugerem ainda uma conduta pratica para o seguimento pre-natal, que deve ser precoce e permitir um amplo esclarecimento dos riscos para a paciente.
Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Pregnancy Complications/prevention & control , Lupus Erythematosus, Cutaneous/congenital , Lupus Erythematosus, Systemic/complications , Therapeutic Approaches/methods , Lupus Erythematosus, Cutaneous/immunology , Lupus Erythematosus, Systemic/classification , Lupus Erythematosus, Systemic/diagnosis , PrognosisABSTRACT
Se estudian 6 pacientes de sexo femenino, con características clínicas e histológicas de lupus eritematoso subagudo. Se encontraron anticuerpos antinucleares positivos en 4 casos y anticuerpos anti RO positivos en 3 casos. Cubrieron criterios para lupus eritematoso sistémico cuatro pacientes. La evolución fue favorable con excepción de un caso con nefropatía severa con anticuerpos anti RO desarrollada tardíamente, en ausencia de anticuerpos anti ADN nativo